| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-185 |
Sentence |
denotes |
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. |
| T1 |
0-185 |
Sentence |
denotes |
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. |
| TextSentencer_T2 |
186-197 |
Sentence |
denotes |
BACKGROUND: |
| T2 |
186-197 |
Sentence |
denotes |
BACKGROUND: |
| TextSentencer_T3 |
198-395 |
Sentence |
denotes |
The detection of circulating tumor cells (CTCs) in the peripheral blood of melanoma patients by quantitative real-time reverse-transcription PCR (qRT-PCR) analysis correlates with a poor prognosis. |
| T3 |
198-395 |
Sentence |
denotes |
The detection of circulating tumor cells (CTCs) in the peripheral blood of melanoma patients by quantitative real-time reverse-transcription PCR (qRT-PCR) analysis correlates with a poor prognosis. |
| TextSentencer_T4 |
396-566 |
Sentence |
denotes |
The assessment of CTCs from blood has been difficult because of lack of a good monoclonal antibody (mAb) directed against surface cell antigens to capture melanoma cells. |
| T4 |
396-566 |
Sentence |
denotes |
The assessment of CTCs from blood has been difficult because of lack of a good monoclonal antibody (mAb) directed against surface cell antigens to capture melanoma cells. |
| TextSentencer_T5 |
567-575 |
Sentence |
denotes |
METHODS: |
| T5 |
567-575 |
Sentence |
denotes |
METHODS: |
| TextSentencer_T6 |
576-697 |
Sentence |
denotes |
Blood was collected prospectively from 57 melanoma patients (43 test and 14 test-development cases) and 5 healthy donors. |
| T6 |
576-697 |
Sentence |
denotes |
Blood was collected prospectively from 57 melanoma patients (43 test and 14 test-development cases) and 5 healthy donors. |
| TextSentencer_T7 |
698-870 |
Sentence |
denotes |
High molecular weight melanoma-associated antigen (HMW-MAA)-specific mAbs bound to immunomagnetic beads were used to isolate CTCs. mRNA and/or DNA were extracted from CTCs. |
| T7 |
698-870 |
Sentence |
denotes |
High molecular weight melanoma-associated antigen (HMW-MAA)-specific mAbs bound to immunomagnetic beads were used to isolate CTCs. mRNA and/or DNA were extracted from CTCs. |
| TextSentencer_T8 |
871-1114 |
Sentence |
denotes |
Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, and MITF) with qRT-PCR and for the presence of BRAFmt (a BRAF gene variant encoding the V600E mutant protein) verified the beads-isolated CTCs to be melanoma cells. |
| T8 |
871-1114 |
Sentence |
denotes |
Testing for the expression of a melanoma-associated gene panel (MLANA, MAGEA3, and MITF) with qRT-PCR and for the presence of BRAFmt (a BRAF gene variant encoding the V600E mutant protein) verified the beads-isolated CTCs to be melanoma cells. |
| TextSentencer_T9 |
1115-1186 |
Sentence |
denotes |
A peptide nucleic acid-clamping PCR assay was used for BRAFmt analysis. |
| T9 |
1115-1186 |
Sentence |
denotes |
A peptide nucleic acid-clamping PCR assay was used for BRAFmt analysis. |
| TextSentencer_T10 |
1187-1195 |
Sentence |
denotes |
RESULTS: |
| T10 |
1187-1195 |
Sentence |
denotes |
RESULTS: |
| TextSentencer_T11 |
1196-1488 |
Sentence |
denotes |
Spiking of peripheral blood cells (PBCs) with melanoma cells showed that the beads-based detection assay can detect approximately 1 melanoma cell in 5 x 10(6) PBCs. qRT-PCR analysis detected MLANA, MAGEA3, and MITF expression in 19 (44%), 29 (67%), and 19 (44%) of the patients, respectively. |
| T11 |
1196-1488 |
Sentence |
denotes |
Spiking of peripheral blood cells (PBCs) with melanoma cells showed that the beads-based detection assay can detect approximately 1 melanoma cell in 5 x 10(6) PBCs. qRT-PCR analysis detected MLANA, MAGEA3, and MITF expression in 19 (44%), 29 (67%), and 19 (44%) of the patients, respectively. |
| TextSentencer_T12 |
1489-1578 |
Sentence |
denotes |
At least one biomarker of the panel was positive in 40 (93%) of the 43 melanoma patients. |
| T12 |
1489-1578 |
Sentence |
denotes |
At least one biomarker of the panel was positive in 40 (93%) of the 43 melanoma patients. |
| TextSentencer_T13 |
1579-1657 |
Sentence |
denotes |
BRAFmt was detected in 17 (81%) of the 21 assessed stage IV melanoma patients. |
| T13 |
1579-1657 |
Sentence |
denotes |
BRAFmt was detected in 17 (81%) of the 21 assessed stage IV melanoma patients. |
| TextSentencer_T14 |
1658-1669 |
Sentence |
denotes |
CONCLUSION: |
| T14 |
1658-1669 |
Sentence |
denotes |
CONCLUSION: |
| TextSentencer_T15 |
1670-1848 |
Sentence |
denotes |
The assay of bead capture coupled with the PCR has utility for assessing CTCs in melanoma patients, which can then be characterized for both genomic and transcriptome expression. |
| T15 |
1670-1848 |
Sentence |
denotes |
The assay of bead capture coupled with the PCR has utility for assessing CTCs in melanoma patients, which can then be characterized for both genomic and transcriptome expression. |